造影剤の世界市場(~2026年):種類別(ヨウ素化造影剤)、モダリティ別(X線/CT、MRI、超音波)、用途別(放射線)、エンドユーザー別(病院)、疾患別(癌)、投与経路別(経口)、地域別

調査会社MarketsandMarkets社が発行したリサーチレポート(データ管理コード:MD3577)
◆英語タイトル:Contrast Media/Contrast Agent Market by Type (Iodinated Contrast Media), Modality (X-Ray/CT, MRI, and Ultrasound), Application (Radiology), End User (Hospitals), Indication (Cancer), Route of Administration (Oral), Region - Global Forecast to 2026
◆発行会社/調査会社:MarketsandMarkets
◆商品コード:MD3577
◆発行日:2021年7月20日
◆調査対象地域:グローバル
◆産業分野:医薬品
◆ページ数:287
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[造影剤の世界市場(~2026年):種類別(ヨウ素化造影剤)、モダリティ別(X線/CT、MRI、超音波)、用途別(放射線)、エンドユーザー別(病院)、疾患別(癌)、投与経路別(経口)、地域別]についてメールでお問い合わせはこちら
マーケッツアンドマーケッツ社は、造影剤の世界市場規模が2021年49億ドルから2026年59億ドルまで、年平均3.7%成長すると予測しています。本調査レポートは、世界の造影剤市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別(ヨウ素化造影剤、ガドリニウム系造影剤、マイクロバブル造影剤、バリウム系造影剤)分析、モダリティ別(X線/CT、MRI、超音波)分析、投与経路別(血管内経路、経口経路、直腸経路、その他)分析、疾患別(心血管疾患、癌、胃腸疾患、筋骨格疾患、神経疾患)分析、地域別分析、競争状況、企業情報など、以下の構成でまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・造影剤の世界市場規模:種類別(ヨウ素化造影剤、ガドリニウム系造影剤、マイクロバブル造影剤、バリウム系造影剤)
・造影剤の世界市場規模:モダリティ別(X線/CT、MRI、超音波)
・造影剤の世界市場規模:投与経路別(血管内経路、経口経路、直腸経路、その他)
・造影剤の世界市場規模:疾患別(心血管疾患、癌、胃腸疾患、筋骨格疾患、神経疾患)
・造影剤の世界市場規模:地域別
・競争状況
・企業情報
*** レポート概要(サマリー)***

“The global contrast media/ contrast agents market is projected to reach USD 5.9 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 3.7% during the forecast period.”  The growth in this market can be attributed to the rising prevalence of chronic diseases, growing approvals of contrast agents, rising volume of CT and MRI examinations performed, growing number of diagnostic centers and hospitals, and availability of reimbursement. Emerging markets in Asian countries are expected to offer strong growth opportunities for players in the market. In contrast, high cost and inaccessibility of advanced therapeutics may restrict market growth to a certain extent. The contrast media/ contrast agents market is segmented based on type, modality, route of administration, indication, application, end user, and region.

“Iodinated contrast media segment is expected to dominate the market during the forecast period.”
Based on type, the contrast media/ contrast agents market is segmented into iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barum-based contrast media. Iodinated contrast media account for the largest share of the contrast media/ contrast agents market. The large share of this segment can be attributed to the growing number of angioplasty procedures performed globally.

“X-ray/ CT segment to dominate the market during the forecast period.”

Based on modality, contrast media/ contrast agents can be segmented into X-ray/CT, MRI and Ultrasound.X-ray/CT account for the largest share of the contrast media/ contrast agents market. The large share of this segment can be attributed to the increasing number of CT examinations across the globe, coupled with advancements in CT imaging technologies that majorly use injectable contrast media.

“Intravascular route segment holds highest market share during the forecast period and is also expected to grow at the highest CAGR during the forecast period.”

Based on routes of administration, the contrast media/contrast agents market is segmented into oral, intravascular, rectal, and other routes of administration. The intravascular route segment is expected to hold majority of market share and have highest growth rate. The widespread use of injectable contrast media in most modern imaging modalities, such as CT and MRI scanning, is one of the major factors driving the growth of the intravascular segment.

“Cardiovascular disorders segment holds highest market share during the forecast period and is also expected to grow at the highest CAGR during the forecast period.”

Based on indication, the contrast media/contrast agents market has been segmented into cardiovascular disorders, cancer, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. Cardiovascular disorders accounted for the largest market share and highest growth rate. The large share of this segment can be attributed to the rising geriatric population and the increasing prevalence of CVD across the globe.

“Radiology segment to dominate the market during the forecast period.”

Based on application, the contrast media/contrast agents market is segmented into radiology, interventional radiology, and interventional cardiology.The radiology applications segment commanded the largest share of the contrast media/contrast agents market. .The large share of this segment can be attributed to the increasing use of medical imaging techniques, such as X-ray, CT, MRI, and ultrasound, in these applications.

“Hospitals, Clinics & Ambulatory Surgery Centers segment to dominate the market during the forecast period.”

Based on end user, the contrast media/contrast agents market is segmented into hospitals, clinics, and ASCs and diagnostic imaging centers. Hospitals, clinics, and ASCs for the largest share of the contrast media/ contrast agents market. The large share is attributed to rising number of hospitals across the globe.

“North America will dominate the market during the forecast period.”

The global contrast media/ contrast agents market is segmented into North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of Asia Pacific), Latin America and Middle East & Africa. In 2020, North America dominated the global contrast media/ contrast agents market, followed by Europe. The large share of the North American market can be attributed to the presence of major players in the region, high prevalence of chronic disorders, growing geriatric population, and the increasing adoption of minimally invasive procedures.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type -Tier 1: 55%,Tier 2: 25% and Tier 20%
• By Designation – C-level:43%, D-level:32%, and Others:25%
• By Region – North America:38%, Europe:23%, Asia Pacific:29%, Latin America: 7%, and Middle East & Africa: 3%

List of Companies Profiled in the Report
• GE Healthcare (US)
• Bracco Imaging SPA (Italy)
• Bayer AG (Germany)
• Guerbet (France)
• Lantheus Medical Imaging, Inc. (US)
• Unijules Life Sciences (India)
• J.B. Chemicals and Pharmaceuticals Ltd. (India)
• SANOCHEMIA Pharmazeutika GmbH (Austria)
• Taejoon Pharm (South Korea)
• JodasExpoim (India)
• Nano Therapeutics Pvt. Ltd. (India)
• Kiran X-ray (India)
• iMax Diagnostic Imaging Limited (Ireland)
• YZJ Group (China)
• Livealth Biopharma Pvt. Ltd. (India)
• Trivitron Healthcare Pvt. Ltd. (India)
• Novalek Pharmaceuticals Pvt. Ltd. (India)
• Unispire Biopharma Private Limited (India)
• Acro Lifesciences (I) Pvt. Ltd. (India)
• Congruent Pharmachem Private Limited (India)
• Stanex Drugs & Chemical Pvt. Ltd. (India)
• Beijing Beilu Pharmaceutical Co., Ltd. (China)
• Rege Imaging & Cine Films Private Limited (India)
• K DIAM EXIM (India)
• Onko İlaç San. ve Tic. A.Ş. (Turkey)
• Subhra Pharma Pvt. Ltd. (India)

Research Coverage:
This report provides a detailed picture of the global contrast media/ contrast agentsmarket. It aims at estimating the size and future growth potential of the market across different segments, such astype, modality, route of administration, indication, application, end userand region. The report also analyzes factors (such as drivers, restraints,opportunities and challenges) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total contrast media/ contrast agents market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on contrast media/ contrast agents offered by the top 26 players in the contrast media/ contrast agents market. The report analyses the contrast media/ contrast agentsmarket by product, modality, route of administration, indication, application, end userand region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various contrast media/ contrast agentsacross key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the contrast media/ contrast agentsmarket.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the contrast media/ contrast agentsmarket.

*** レポート目次(コンテンツ)***

1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 41
1.3 MARKET SCOPE 42
FIGURE 1 CONTRAST MEDIA/CONTRAST AGENTS MARKET SEGMENTATION 42
1.3.1 YEARS CONSIDERED FOR THE STUDY 43
1.4 CURRENCY 43
1.5 STAKEHOLDERS 43
1.6 SUMMARY OF CHANGES 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
FIGURE 2 RESEARCH DESIGN 45
2.2 SECONDARY DATA 46
2.2.1 SECONDARY SOURCES 47
2.3 PRIMARY DATA 48
FIGURE 3 PRIMARY SOURCES 48
2.3.1 KEY DATA FROM PRIMARY SOURCES 49
2.3.2 KEY INDUSTRY INSIGHTS 50
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 50
2.4 MARKET SIZE ESTIMATION 51
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 51
2.4.1 GROWTH FORECAST 52
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 52
FIGURE 7 TOP-DOWN APPROACH 53
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 54
FIGURE 8 DATA TRIANGULATION METHODOLOGY 54
2.6 MARKET SHARE ANALYSIS 54
2.7 ASSUMPTIONS FOR THE STUDY 55
2.7.1 COVID-19 SPECIFIC ASSUMPTIONS 55
2.8 LIMITATIONS 56
2.9 RISK ASSESSMENT 56
2.10 GROWTH RATE ASSUMPTIONS 57
2.11 COVID-19 ECONOMIC ASSESSMENT 57
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 57
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 57
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 59
3 EXECUTIVE SUMMARY 60
FIGURE 11 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 60
FIGURE 12 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY,
2021 VS. 2026 (USD MILLION) 61
FIGURE 13 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD MILLION) 62
FIGURE 14 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION,
2021 VS. 2026 (USD MILLION) 63
FIGURE 15 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 64
FIGURE 16 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 65
FIGURE 17 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION,
2021 VS. 2026 (USD MILLION) 66
4 PREMIUM INSIGHTS 67
4.1 CONTRAST MEDIA/CONTRAST AGENTS MARKET OVERVIEW 67
FIGURE 18 INCREASING INCIDENCE OF CHRONIC DISORDERS TO DRIVE MARKET GROWTH 67
4.2 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE (2021–2026) 68
FIGURE 19 MICROBUBBLE CONTRAST MEDIA SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 68
4.3 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE AND COUNTRY (2020) 69
FIGURE 20 THE US DOMINATED THE NORTH AMERICAN CONTRAST MEDIA/CONTRAST AGENTS MARKET IN 2020 69
4.4 CONTRAST MEDIA/CONTRAST AGENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 70
FIGURE 21 INDIA AND CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 70
5 MARKET OVERVIEW 71
5.1 INTRODUCTION 71
FIGURE 22 CONTRAST MEDIA/CONTRAST AGENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 71
5.2 MARKET DYNAMICS 72
5.2.1 DRIVERS 72
5.2.1.1 Rising prevalence of chronic diseases 72
TABLE 1 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 72
5.2.1.2 Growing approvals of contrast agents 72
5.2.1.3 Rising volume of CT and MRI examinations performed 73
TABLE 2 NUMBER OF MRI EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2010 VS. 2018 74
TABLE 3 NUMBER OF CT EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2010 VS. 2018 74
5.2.1.4 Growing number of diagnostic centers and hospitals 74
5.2.1.5 Availability of reimbursement 75
5.2.2 RESTRAINTS 75
5.2.2.1 Side-effects and allergic reactions associated with contrast agents 75
TABLE 4 LIST OF SIDE-EFFECTS/REACTIONS TO CONTRAST MEDIA 75
5.2.3 OPPORTUNITIES 76
5.2.3.1 Generic contrast media 76
5.2.3.2 Increasing research on contrast agents 77
TABLE 5 INDICATIVE LIST OF RESEARCH STUDIES 77
5.2.4 CHALLENGES 78
5.2.4.1 Technological advancements in imaging solutions 78
5.2.4.2 Restriction and withdrawal of linear gadolinium-based contrast agents 78
5.2.4.3 Dearth of trained professionals 79
TABLE 6 METROPOLITAN AREAS IN THE US WITH HIGH EMPLOYMENT LEVELS AMONG RADIOLOGY TECHNOLOGISTS AND TECHNICIANS 79
5.3 RANGES/SCENARIOS 80
5.3.1 CONTRAST MEDIA/CONTRAST AGENTS MARKET FORECAST 80
FIGURE 23 PESSIMISTIC SCENARIO 80
FIGURE 24 OPTIMISTIC SCENARIO 80
FIGURE 25 REALISTIC SCENARIO 81
5.4 COVID-19 IMPACT ON THE CONTRAST MEDIA/CONTRAST AGENTS MARKET 81
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 83
5.5.1 REVENUE SHIFT & REVENUE POCKETS FOR CONTRAST MEDIA/CONTRAST AGENT MANUFACTURERS 83
5.5.2 REVENUE SHIFT FOR CONTRAST MEDIA/CONTRAST AGENTS MARKET 83
5.6 PRICING ANALYSIS 84
TABLE 7 PRICES OF CONTRAST MEDIA/CONTRAST AGENTS 84
5.7 SUPPLY CHAIN ANALYSIS 84
FIGURE 26 DIRECT DISTRIBUTION: A STRATEGY PREFERRED BY PROMINENT COMPANIES 85
5.8 VALUE CHAIN ANALYSIS 85
FIGURE 27 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE DEVELOPMENT PHASE 86
5.9 ECOSYSTEM ANALYSIS 86
5.9.1 ROLE IN THE ECOSYSTEM 87
TABLE 8 ROLE OF KEY PLAYERS IN THE ECOSYSTEM 87
FIGURE 28 KEY PLAYERS IN THE CONTRAST MEDIA/CONTRAST AGENTS ECOSYSTEM 88
5.10 TECHNOLOGY ANALYSIS 88
5.11 PATENT ANALYSIS 89
5.12 TRADE ANALYSIS 90
TABLE 9 IMPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS; DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2016-2020 (USD MILLION) 90
TABLE 10 EXPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS; DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2016-2020 (USD MILLION) 90
5.13 REGULATORY LANDSCAPE 90
TABLE 11 LIST OF REGULATORY AUTHORITIES IN THE PHARMACEUTICAL INDUSTRY 91
5.13.1 EU REGULATIONS 92
5.13.2 FDA REGULATIONS 92
5.13.3 JPMA REGULATIONS 93
5.14 PORTER’S FIVE FORCES ANALYSIS 93
TABLE 12 PORTER’S FIVE FORCES 93
5.14.1 INTENSITY OF COMPETITIVE RIVALRY 93
5.14.2 BARGAINING POWER OF SUPPLIERS 93
5.14.3 BARGAINING POWER OF BUYERS 93
5.14.4 THREAT OF SUBSTITUTES 93
5.14.5 THREAT OF NEW ENTRANTS 94
6 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE 95
6.1 INTRODUCTION 96
6.2 PRIMARY NOTES 96
TABLE 13 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2017–2019 (USD MILLION) 96
TABLE 14 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2020–2026 (USD MILLION) 97
6.3 IODINATED CONTRAST MEDIA 97
6.3.1 CONSUMPTION OF IODINATED CONTRAST MEDIA IS HIGH DUE TO THE HIGHER DOSAGE REQUIRED IN CT SCANS—A KEY FACTOR DRIVING MARKET GROWTH 97
TABLE 15 IODINATED CONTRAST MEDIA MARKET, BY REGION,
2017–2019 (USD MILLION) 98
TABLE 16 IODINATED CONTRAST MEDIA MARKET, BY REGION,
2020–2026 (USD MILLION) 98
6.4 GADOLINIUM-BASED CONTRAST MEDIA 99
6.4.1 SUSPICION REGARDING THE SAFETY PROFILE OF GADOLINIUM-BASED CONTRAST AGENTS TO CHALLENGE MARKET GROWTH TO A CERTAIN EXTENT 99
TABLE 17 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY REGION,
2017–2019 (USD MILLION) 100
TABLE 18 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY REGION,
2020–2026 (USD MILLION) 100
6.5 MICROBUBBLE CONTRAST MEDIA 100
6.5.1 MICROBUBBLES ARE CONVENIENT, COMPLETELY RADIATION-FREE, AND VERSATILE, MAKING THEM EXTREMELY POPULAR WITH PHYSICIANS WORLDWIDE 100
TABLE 19 MICROBUBBLE CONTRAST MEDIA MARKET, BY REGION,
2017–2019 (USD MILLION) 101
TABLE 20 MICROBUBBLE CONTRAST MEDIA MARKET, BY REGION,
2020–2026 (USD MILLION) 101
6.6 BARIUM-BASED CONTRAST MEDIA 102
6.6.1 BARIUM-BASED CONTRAST MEDIA CAN CAUSE ADVERSE EFFECTS IN PATIENTS LIKE PERFORATION OF THE PERITONEUM—THIS IS EXPECTED TO NEGATIVELY IMPACT THE MARKET 102
TABLE 21 BARIUM-BASED CONTRAST MEDIA MARKET, BY REGION,
2017–2019 (USD MILLION) 102
TABLE 22 BARIUM-BASED CONTRAST MEDIA MARKET, BY REGION,
2020–2026 (USD MILLION) 103
7 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY 104
7.1 INTRODUCTION 105
7.2 PRIMARY NOTES 105
TABLE 23 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY,
2017–2019 (USD MILLION) 105
TABLE 24 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY,
2020–2026 (USD MILLION) 106
7.3 X-RAY/CT 106
7.3.1 X-RAY/CT SEGMENT ACCOUNTS FOR THE LARGEST SHARE OF THE CONTRAST MEDIA/CONTRAST AGENTS MARKET 106
TABLE 25 NUMBER OF X-RAY AND CT SCANS IN ENGLAND 107
TABLE 26 INSTALLED BASE OF CT SCANNERS, BY REGION, 2017 VS. 2018 107
TABLE 27 CT PROCEDURAL VOLUMES, BY REGION, 2017 VS. 2018 (MILLION) 107
TABLE 28 X-RAY/CT CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2017–2019 (USD MILLION) 107
TABLE 29 X-RAY/CT CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2020–2026 (USD MILLION) 108
7.4 MAGNETIC RESONANCE IMAGING 108
7.4.1 GROWING NUMBER OF MRI SCANNERS AND INCREASING MRI EXAMINATIONS ARE DRIVING MARKET GROWTH 108
TABLE 30 INSTALLED BASE OF MRI SYSTEMS, BY REGION, 2017 VS. 2018 109
TABLE 31 MRI PROCEDURAL VOLUMES, BY REGION, 2017 VS. 2018 (MILLION) 109
TABLE 32 NUMBER OF MRI PROCEDURES IN ENGLAND 109
TABLE 33 MRI CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION,
2017–2019 (USD MILLION) 110
TABLE 34 MRI CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION,
2020–2026 (USD MILLION) 110
7.5 ULTRASOUND 110
7.5.1 ULTRASOUND SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 110
TABLE 35 NUMBER OF ULTRASOUND PROCEDURES IN ENGLAND 111
TABLE 36 ULTRASOUND CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2017–2019 (USD MILLION) 112
TABLE 37 ULTRASOUND CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2020–2026 (USD MILLION) 112

8 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION 113
8.1 INTRODUCTION 114
TABLE 38 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 114
TABLE 39 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 114
8.2 INTRAVASCULAR ROUTE 115
8.2.1 WIDESPREAD USE OF INTRAVASCULAR ROUTES OF ADMINISTRATION IN IMAGING MODALITIES TO DRIVE MARKET GROWTH 115
8.2.1.1 INTRAVENOUS (IV) ROUTE 115
8.2.1.2 INTRA-ARTERIAL (IA) ROUTE 115
TABLE 40 INTRAVASCULAR CONTRAST MEDIA MARKET, BY REGION,
2017–2019 (USD MILLION) 116
TABLE 41 INTRAVASCULAR CONTRAST MEDIA MARKET, BY REGION,
2020–2026 (USD MILLION) 116
8.3 ORAL ROUTE 116
8.3.1 USE OF ORAL CONTRAST MEDIA CAN LEAD TO PERFORATIONS IN THE GIT, LEADING TO PERITONITIS—THIS MAY LIMIT MARKET GROWTH TO A CERTAIN EXTENT 116
TABLE 42 ORAL CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION) 117
TABLE 43 ORAL CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION) 117
8.4 RECTAL ROUTE 118
8.4.1 MILD DISCOMFORT ASSOCIATED WITH RECTAL CONTRAST MEDIA TO LIMIT MARKET GROWTH 118
TABLE 44 RECTAL CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION) 118
TABLE 45 RECTAL CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION) 119
8.5 OTHER ROUTES OF ADMINISTRATION 119
TABLE 46 OTHER CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION) 119
TABLE 47 OTHER CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION) 120
9 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION 121
9.1 INTRODUCTION 122
9.2 PRIMARY NOTES 122
TABLE 48 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION,
2017–2019 (USD MILLION) 122
TABLE 49 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION,
2020–2026 (USD MILLION) 123
9.3 CARDIOVASCULAR DISORDERS 123
9.3.1 CARDIOVASCULAR DISORDERS SEGMENT TO DOMINATE THE CONTRAST MEDIA/CONTRAST AGENTS MARKET 123
TABLE 50 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2017–2019 (USD MILLION) 124
TABLE 51 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2020–2026 (USD MILLION) 124
9.4 CANCER 124
9.4.1 ASIA PACIFIC MARKET TO REGISTER RELATIVELY HIGHER GROWTH OWING TO THE HIGH CANCER PREVALENCE IN THE REGION 124
TABLE 52 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 125
TABLE 53 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CANCER, BY REGION, 2017–2019 (USD MILLION) 125
TABLE 54 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CANCER, BY REGION, 2020–2026 (USD MILLION) 126
9.5 GASTROINTESTINAL DISORDERS 126
9.5.1 RISING PREVALENCE OF GI DISORDERS TO SUPPORT MARKET GROWTH 126
TABLE 55 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2017–2019 (USD MILLION) 126
TABLE 56 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2020–2026 (USD MILLION) 127
9.6 MUSCULOSKELETAL DISORDERS 127
9.6.1 RISING INCIDENCE OF WORK-RELATED MUSCULOSKELETAL DISORDERS TO SUPPORT MARKET GROWTH 127
TABLE 57 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2017–2019 (USD MILLION) 128
TABLE 58 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020–2026 (USD MILLION) 128
9.7 NEUROLOGICAL DISORDERS 128
9.7.1 RISING PREVALENCE OF DEMENTIA TO DRIVE MARKET GROWTH 128
TABLE 59 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2017–2019 (USD MILLION) 129
TABLE 60 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020–2026 (USD MILLION) 129
9.8 NEPHROLOGICAL DISORDERS 130
9.8.1 RISING PREVALENCE OF ESRD IS DRIVING THE DEMAND FOR DIAGNOSTIC TOOLS FOR KIDNEY DISEASES 130
TABLE 61 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR NEPHROLOGICAL DISORDERS, BY REGION, 2017–2019 (USD MILLION) 130
TABLE 62 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR NEPHROLOGICAL DISORDERS, BY REGION, 2020–2026 (USD MILLION) 131
10 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION 132
10.1 INTRODUCTION 133
TABLE 63 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION,
2017–2019 (USD MILLION) 133
TABLE 64 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 133
10.2 RADIOLOGY 134
10.2.1 GROWING NUMBER OF DIAGNOSTIC PROCEDURES TO DRIVE THE GROWTH OF THE RADIOLOGY APPLICATIONS SEGMENT 134
TABLE 65 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR RADIOLOGY,
BY REGION, 2017–2019 (USD MILLION) 134
TABLE 66 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR RADIOLOGY,
BY REGION, 2020–2026 (USD MILLION) 135
10.3 INTERVENTIONAL RADIOLOGY 135
10.3.1 INCREASING POPULARITY OF MINIMALLY INVASIVE PROCEDURES TO SUPPORT MARKET GROWTH 135
TABLE 67 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2017–2019 (USD MILLION) 136
TABLE 68 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2020–2026 (USD MILLION) 136
10.4 INTERVENTIONAL CARDIOLOGY 136
10.4.1 RISING INCIDENCE OF CARDIAC DISORDERS TO DRIVE THE DEMAND FOR INTERVENTIONAL CARDIOLOGY PROCEDURES 136
TABLE 69 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2017–2019 (USD MILLION) 137
TABLE 70 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2020–2026 (USD MILLION) 138
11 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER 139
11.1 INTRODUCTION 140
TABLE 71 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2017–2019 (USD MILLION) 140
TABLE 72 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2020–2026 (USD MILLION) 140
11.2 HOSPITAL, CLINICS, AND AMBULATORY SURGERY CENTERS 140
11.2.1 INCREASING ADOPTION OF DIAGNOSTIC IMAGING MODALITIES ACROSS HOSPITALS TO DRIVE MARKET GROWTH 140
TABLE 73 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2017–2019 (USD MILLION) 141
TABLE 74 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2020–2026 (USD MILLION) 142
11.3 DIAGNOSTIC IMAGING CENTERS 142
11.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO DRIVE MARKET GROWTH IN THE COMING YEARS 142
TABLE 75 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2017–2019 (USD MILLION) 142
TABLE 76 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2020–2026 (USD MILLION) 143
12 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION 144
12.1 INTRODUCTION 145
TABLE 77 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION,
2017–2019 (USD MILLION) 145
TABLE 78 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION,
2020–2026 (USD MILLION) 145

12.2 NORTH AMERICA 146
FIGURE 29 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET SNAPSHOT 146
TABLE 79 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY COUNTRY, 2017–2019 (USD MILLION) 147
TABLE 80 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY COUNTRY, 2020–2026 (USD MILLION) 147
TABLE 81 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION) 147
TABLE 82 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION) 148
TABLE 83 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY MODALITY, 2017–2019 (USD MILLION) 148
TABLE 84 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY MODALITY, 2020–2026 (USD MILLION) 148
TABLE 85 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 149
TABLE 86 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 149
TABLE 87 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY INDICATION, 2017–2019 (USD MILLION) 149
TABLE 88 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY INDICATION, 2020–2026 (USD MILLION) 150
TABLE 89 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY APPLICATION, 2017–2019 (USD MILLION) 150
TABLE 90 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY APPLICATION, 2020–2026 (USD MILLION) 150
TABLE 91 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY END USER, 2017–2019 (USD MILLION) 151
TABLE 92 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY END USER, 2020–2026 (USD MILLION) 151
12.2.1 US 151
12.2.1.1 The US dominates the North American contrast media/contrast agents market 151
TABLE 93 US: KEY MACROINDICATORS 152
TABLE 94 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2017–2019 (USD MILLION) 152
TABLE 95 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2020–2026 (USD MILLION) 153
TABLE 96 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY,
2017–2019 (USD MILLION) 153
TABLE 97 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY,
2020–2026 (USD MILLION) 153
TABLE 98 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 154
TABLE 99 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 154
TABLE 100 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION,
2017–2019 (USD MILLION) 154
TABLE 101 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION,
2020–2026 (USD MILLION) 155
TABLE 102 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION) 155
TABLE 103 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION) 155
TABLE 104 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2017–2019 (USD MILLION) 156
TABLE 105 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2020–2026 (USD MILLION) 156
12.2.2 CANADA 156
12.2.2.1 Increasing investments in improving medical imaging—a major factor driving market growth in Canada 156
TABLE 106 CANADA: KEY MACROINDICATORS 157
TABLE 107 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2017–2019 (USD MILLION) 157
TABLE 108 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2020–2026 (USD MILLION) 158
TABLE 109 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION) 158
TABLE 110 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION) 158
TABLE 111 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 159
TABLE 112 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 159
TABLE 113 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION) 159
TABLE 114 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION) 160
TABLE 115 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION) 160
TABLE 116 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION) 160
TABLE 117 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION) 161
TABLE 118 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION) 161
12.3 EUROPE 161
TABLE 119 TOTAL NUMBER OF MRI UNITS PER 1,000,000 INHABITANTS, 2017 162
TABLE 120 TOTAL NUMBER OF MRI EXAMS PER 1,000 INHABITANTS, 2017 162
TABLE 121 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2017–2019 (USD MILLION) 162
TABLE 122 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2020–2026 (USD MILLION) 163
TABLE 123 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2017–2019 (USD MILLION) 163
TABLE 124 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2020–2026 (USD MILLION) 164
TABLE 125 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION) 164
TABLE 126 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION) 164
TABLE 127 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 165
TABLE 128 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 165
TABLE 129 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION) 165
TABLE 130 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION) 166
TABLE 131 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION) 166
TABLE 132 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION) 166
TABLE 133 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION) 167
TABLE 134 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION) 167
12.3.1 GERMANY 167
12.3.1.1 Presence of a well-developed diagnostic imaging infrastructure is a major factor supporting market growth in Germany 167
TABLE 135 GERMANY: KEY MACROINDICATORS 168
TABLE 136 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2017–2019 (USD MILLION) 168
TABLE 137 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2020–2026 (USD MILLION) 169
TABLE 138 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION) 169
TABLE 139 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION) 169
TABLE 140 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 170
TABLE 141 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 170
TABLE 142 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION) 170
TABLE 143 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION) 171
TABLE 144 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY APPLICATION, 2017–2019 (USD MILLION) 171
TABLE 145 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET,
BY APPLICATION, 2020–2026 (USD MILLION) 171
TABLE 146 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION) 172
TABLE 147 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION) 172
12.3.2 UK 172
12.3.2.1 Increasing investments in the field of diagnostic imaging to boost the market growth 172
TABLE 148 UK: KEY MACROINDICATORS 173
TABLE 149 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2017–2019 (USD MILLION) 173
TABLE 150 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2020–2026 (USD MILLION) 174
TABLE 151 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY,
2017–2019 (USD MILLION) 174
TABLE 152 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY,
2020–2026 (USD MILLION) 174
TABLE 153 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 175
TABLE 154 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 175
TABLE 155 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION,
2017–2019 (USD MILLION) 175
TABLE 156 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION,
2020–2026 (USD MILLION) 176
TABLE 157 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION) 176
TABLE 158 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION) 176
TABLE 159 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2017–2019 (USD MILLION) 177
TABLE 160 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2020–2026 (USD MILLION) 177
12.3.3 FRANCE 177
12.3.3.1 Increasing prevalence of cancer will drive the market for contrast media in France 177
TABLE 161 FRANCE: KEY MACROINDICATORS 178
TABLE 162 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2017–2019 (USD MILLION) 178
TABLE 163 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2020–2026 (USD MILLION) 178
TABLE 164 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION) 179
TABLE 165 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION) 179
TABLE 166 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 179
TABLE 167 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 180
TABLE 168 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION) 180
TABLE 169 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION) 181
TABLE 170 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION) 181
TABLE 171 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION) 181
TABLE 172 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION) 182
TABLE 173 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION) 182
12.3.4 SPAIN 182
12.3.4.1 Shortage of radiologists in the country to restrain the market growth 182
TABLE 174 SPAIN: KEY MACROINDICATORS 183
TABLE 175 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2017–2019 (USD MILLION) 183
TABLE 176 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2020–2026 (USD MILLION) 183
TABLE 177 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION) 184
TABLE 178 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION) 184
TABLE 179 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 184
TABLE 180 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 185
TABLE 181 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION) 185
TABLE 182 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION) 186
TABLE 183 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION) 186
TABLE 184 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION) 186
TABLE 185 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION) 187
TABLE 186 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION) 187
12.3.5 ITALY 187
12.3.5.1 Rising geriatric population likely to drive the demand for diagnostic procedures in Italy 187
TABLE 187 ITALY: KEY MACROINDICATORS 188
TABLE 188 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2017–2019 (USD MILLION) 188
TABLE 189 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2020–2026 (USD MILLION) 188
TABLE 190 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY,
2017–2019 (USD MILLION) 189
TABLE 191 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION) 189
TABLE 192 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 189
TABLE 193 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 190
TABLE 194 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION) 190
TABLE 195 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION) 191
TABLE 196 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION) 191
TABLE 197 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION) 191
TABLE 198 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2017–2019 (USD MILLION) 192
TABLE 199 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2020–2026 (USD MILLION) 192
12.3.6 REST OF EUROPE 192
TABLE 200 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP) 193
TABLE 201 ROE: NUMBER OF UNITS AND NUMBER OF SCANS, BY COUNTRY, 2018 193
TABLE 202 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2017–2019 (USD MILLION) 193
TABLE 203 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,
2020–2026 (USD MILLION) 194
TABLE 204 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY,
2017–2019 (USD MILLION) 194
TABLE 205 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY,
2020–2026 (USD MILLION) 194
TABLE 206 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION) 195
TABLE 207 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION) 195
TABLE 208 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION) 195
TABLE 209 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION) 196
TABLE 210 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION) 196
TABLE 211 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION) 196
TABLE 212 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2017–2019 (USD MILLION) 197
TABLE 213 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER,
2020–2026 (USD MILLION) 197



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(MD3577 )"造影剤の世界市場(~2026年):種類別(ヨウ素化造影剤)、モダリティ別(X線/CT、MRI、超音波)、用途別(放射線)、エンドユーザー別(病院)、疾患別(癌)、投与経路別(経口)、地域別" (英文:Contrast Media/Contrast Agent Market by Type (Iodinated Contrast Media), Modality (X-Ray/CT, MRI, and Ultrasound), Application (Radiology), End User (Hospitals), Indication (Cancer), Route of Administration (Oral), Region - Global Forecast to 2026)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。